# CoreRX Inc. - Inspection Records

Source: https://www.keypedia.com/companies/corerx-inc/cca4f858-9ccd-498a-893b-22c5d29559aa

> Inspection records and compliance data for CoreRX Inc. in Clearwater, Florida. Access full analysis and detailed observations.

---

## Details

- Name: CoreRX Inc.
- FEI Number: 3007209985
- City: Clearwater
- State: Florida
- Country Name: United States
- Address Line 1: 14205 Myerlake Cir
- Zip Code: 33760
- Business Operations: API/FDF ANALYTICAL TESTING, CLINICAL BIOEQUIVALENCE OR BIOAVAILABILITY STUDY, FDF MANUFACTURE, IN VITRO BIOEQUIVALENCE OR BIOANALYTICAL TESTING, PACK, REPACK

## Related Documents

- [483 - CoreRX Inc. - 2026-02-26](https://www.keypedia.com/records/483/corerx-inc/f623fd94-2144-4fc8-860e-edd827c6ad95) — source: FDA, date: February 26, 2026
- [FDA Inspection 1304588 - CoreRX Inc. - 2026-02-26](https://www.keypedia.com/records/fda_inspections/corerx-inc/956f34ef-816f-43f4-bdfd-ba4552b1e37e) — source: FDA, date: February 26, 2026
- [483 - CoreRX Inc. - 2025-03-20](https://www.keypedia.com/records/483/corerx-inc/edfc4c2a-ac55-4dee-8c2f-122fff2c1404) — source: FDA, date: March 20, 2025
- [483 - CoreRX Inc. - 2025-03-20](https://www.keypedia.com/records/483/corerx-inc/4e925761-65a5-468e-a5d9-c170685d7857) — source: FDA, date: March 20, 2025
- [FDA Inspection 1264769 - CoreRX Inc. - 2025-03-20](https://www.keypedia.com/records/fda_inspections/corerx-inc/2ad11a9c-e4df-4503-8667-a3b01206638f) — source: FDA, date: March 20, 2025
- [FDA Inspection 1151289 - CoreRX Inc. - 2021-08-13](https://www.keypedia.com/records/fda_inspections/corerx-inc/85fa8ce0-d79f-4073-a991-3e6bc3437b59) — classification: No Action Indicated (NAI), source: FDA, date: August 13, 2021
- [483 - CoreRX Inc. - 2020-03-06](https://www.keypedia.com/records/483/corerx-inc/c5d7672d-dfb4-4e43-ac1d-b08c5c9efdb1) — source: FDA, date: March 6, 2020
- [FDA Inspection 1119912 - CoreRX Inc. - 2020-03-06](https://www.keypedia.com/records/fda_inspections/corerx-inc/bc103bf0-449a-4325-ade3-a111f8251fb5) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 6, 2020
- [483 - CoreRX Inc. - 2019-06-21](https://www.keypedia.com/records/483/corerx-inc/4c534536-5911-42dd-8cf5-a28e860ef746) — source: FDA, date: June 21, 2019
- [483 - CoreRX Inc. - 2019-06-14](https://www.keypedia.com/records/483/corerx-inc/7f68df2f-6919-4a4a-9d5d-425416d88e52) — source: FDA, date: June 14, 2019
- [FDA Inspection 1027540 - CoreRX Inc. - 2017-09-27](https://www.keypedia.com/records/fda_inspections/corerx-inc/5dc2a719-2d30-4fea-aac4-3d3b22c4b12e) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 27, 2017
- [FDA Inspection 932712 - CoreRX Inc. - 2015-06-19](https://www.keypedia.com/records/fda_inspections/corerx-inc/73d46fa9-2206-4650-9918-4d734a61927a) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 19, 2015
- [FDA Inspection 932712 - CoreRX Inc. - 2015-06-19](https://www.keypedia.com/records/fda_inspections/corerx-inc/e6befd13-5536-46d5-a551-1251f167a126) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 19, 2015
- [FDA Inspection 932712 - CoreRX Inc. - 2015-06-19](https://www.keypedia.com/records/fda_inspections/corerx-inc/0223820a-068a-4561-a464-531862e6f326) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 19, 2015
- [483 - CoreRX Inc. - 2014-01-24](https://www.keypedia.com/records/483/corerx-inc/ab98b6ba-9be2-497c-bee5-bc2f3c60eef0) — source: FDA, date: January 24, 2014

## Related Companies

- [Gland Pharma Limited, Units I+II Pashamylaram Site](https://www.keypedia.com/companies/gland-pharma-limited-units-iii-pashamylaram-site/a7dffca3-c5cc-4802-9cab-54995e7133ca)
- [Glenmark Pharmaceuticals Limited](https://www.keypedia.com/companies/glenmark-pharmaceuticals-limited/66c964bb-f670-493b-ab86-aa8507e68a5d)
- [MassBiologics](https://www.keypedia.com/companies/massbiologics/fa584e7c-22de-470c-836a-dd3028fae600)
- [Catalent Belgium SA](https://www.keypedia.com/companies/catalent-belgium-sa/f48653bf-84a2-4aeb-bdc3-ca2d0cc4fdf2)
- [Jubilant HollisterStier LLC](https://www.keypedia.com/companies/jubilant-hollisterstier-llc/2f8cb6dd-3555-4528-a2d6-d3b845d229ba)
- [Patheon Manufacturing Services LLC](https://www.keypedia.com/companies/patheon-manufacturing-services-llc/64087a9c-0f9c-44d7-aeb9-171f7bc13658)
- [Mylan Laboratories Limited](https://www.keypedia.com/companies/mylan-laboratories-limited/4fd10a2e-3696-4bd0-82aa-e875143028c0)
- [Siegfried El Masnou, S.A.](https://www.keypedia.com/companies/siegfried-el-masnou-sa/7d454af3-32c0-4c5d-b7cb-c11d6cd5096b)
- [Novitium Pharma LLC](https://www.keypedia.com/companies/novitium-pharma-llc/056d60b0-f42a-4b34-987f-749ffff0520a)
- [Rovi Pharma Industrial Services S.A.](https://www.keypedia.com/companies/rovi-pharma-industrial-services-sa/947a0616-87f8-4886-a6c2-278c5e678192)

## Related Officers

- [investigator](https://www.keypedia.com/people/mizanne-e-lewis/c79964ac-5163-44a2-89e9-8cc8775de9b4)
- [Approval Manager](https://www.keypedia.com/people/michael-h-tollon/5e30e7e1-5727-4169-8faf-e5d5783ac781)
- [Jennifer Bridgewater, Assoc. Dir. for Reg. Policy](https://www.keypedia.com/people/jennifer-bridgewater-assoc-dir-for-reg-policy/573a7b9f-6b6d-427c-9893-2b5a3b758ed0)
- [Laura Fortun, CSO](https://www.keypedia.com/people/laura-fortun-cso/66af427d-5dc3-4270-97b5-376dd1b55cf7)
- [Naveen B Kanthamneni](https://www.keypedia.com/people/naveen-b-kanthamneni/b6ac825f-1ec8-4857-b772-86ae2c6ea1cd)
- [Jose F. Velez](https://www.keypedia.com/people/jose-f-velez/0d1951e8-3aa5-48ff-bc54-1fae8a7a57c9)